The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: From nature to laboratory

Current Pharmaceutical Design

Volumn 22, Issue 12, 2016, Pages 1756-1766

  Khan, Mohammed I ^a   Sobocińska, Anna A ^a   Czarnecka, Anna M ^a   Król, Magdalena ^b   Botta, Bruno ^c   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cannabinoids; CB1 and CB2 receptors; Endocannabinoid system; Renal cell carcinoma

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOL; DRONABINOL; ENDOCANNABINOID; PHYTOCANNABINOID; RIMONABANT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER THERAPY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; CARCINOMA, RENAL CELL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; KIDNEY NEOPLASMS; SYNTHESIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; CARCINOMA, RENAL CELL; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCANNABINOIDS; HUMANS; KIDNEY NEOPLASMS; MOLECULAR STRUCTURE;

EID: 84964270335     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151211094901     Document Type: Review

References (121)

1. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 2011; 163(7): 1447-63.
2. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc 1964; 86(8): 1646.
3. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78(5): 539-48.
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284): 561-4.
5. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3(10): 745-55.
6. Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 1999; 56(6): 1362-9.
7. Mechoulam R. Marihuana chemistry. Science 1970; 168(3936): 1159-66.
8. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946-9.
9. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50(1): 83-90.
10. Fellermeier M, Eisenreich W, Bacher A, Zenk MH. Biosynthesis of cannabinoids. Incorporation experiments with (13)C-labeled glucoses. Eur J Biochem FEBS 2001; 268(6): 1596-604.
11. Dewick PM. The Acetate Pathway: Fatty Acids and Polyketides. In: Medicinal Natural Products: A Biosynthetic Approach. 3 ed. England: John Wiley & Sons, Ltd 2009.
12. Mechoulam R, Braun P, Gaoni Y. A stereospecific synthesis of (-)-delta 1-and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc 1967; 89(17): 4552-4.
13. Petrzilk T, Haeflige W, Sikemeie C. Synthesis of Hashish Constituents.4. Helv Chim Acta 1969; 52(4): 1102.
14. Razdn RK, Puttick AJ, Zitko BA, Handrick GR. Hashish VI 1: conversion of (-)-1(6)-tetrahydrocannabinol to (-)-1(7)-tetrahydrocannabinol. Stability of (-)-1-and (-)-1(6)-tetrahydrocannabinols. Experientia 1972; 28(2): 121-2.
15. Razdan RK, Handrick GR. Hashish-a Stereospecific Synthesis of (-)-Delta-1-and (-)-Delta-1(6)-Tetrahydrocannabinols. J Am Chem Soc 1970; 92(20): 6061.
16. Razdan RK. The Total Synthesis of Cannabinoids. In: Apsimon J, Ed. Total Synthesis of Natural Products. 4th ed. USA: John Wiley & Sons, Inc.; 1981.
17. Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta9-tetrahydrocannabinol and cannabinol in man. Pharmacology 1975; 13(6): 502-12.
18. McCallum ND, Yagen B, Levy S, Mechoulam R. Cannabinol: a rapidly formed metabolite of delta-1-and delta-6-tetrahydrocannabinol. Experientia 1975; 31(5): 520-1.
19. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012; 367(1607): 3364-78.
20. Mechoulam R, Ben-Zvi Z, Gaoni Y. Hashish--13. On the nature of the Beam test. Tetrahedron 1968; 24(16): 5615-24.
21. Gaoni Y, Mechoula.R. Hashish.7. Isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 1966; 22(4): 1481.
22. Baek SH, Srebnik M, Mechoulam R. Boron-Trifluoride etherate on alimina-a modified lewis acid reagent-an improved synthesis of cannabidiol. Tetrahedron Lett 1985; 26(8): 1083-6.
23. Kobayashi Y, Takeuchi A, Wang YG. Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate. Org Lett 2006; 8(13): 2699-702.
24. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2013; 75(2): 303-12.
25. Fernandez-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013; 75(2): 323-33.
26. Reisenberg M, Singh PK, Williams G, Doherty P. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2012; 367(1607): 3264-75.
27. Devane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem 1992; 35(11): 2065-9.
28. Huffman JW. Cannabimimetic indoles, pyrroles, and indenes: Structure-activity relationships and receptor interactions. In: Reggio PH, Ed. The Cannabionoid Receptors. New York: Humana Press 2009.
29. Gonzalez-Naranjo P, Campillo NE, Perez C, Paez JA. Multitarget cannabinoids as novel strategy for Alzheimer disease. Curr Alzheimer Res 2013; 10(3): 229-39.
30. Vidinsky B, Gal P, Pilatova M, et al. Anti-proliferative and antiangiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol 2012; 58(2): 75-80.
31. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395(6700): 381-3.
32. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes (Lond) 2009; 33(9): 947-55.
33. Yoshioka T, Fujita T, Kanai T, et al. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 1989; 32(2): 421-8.
34. Graham ES, Ashton JC, Glass M. Cannabinoid receptors: a brief history and "what's hot". Front Biosci (Landmark Ed) 2009; 14: 944-57.
35. Flygare J, Sander B. The endocannabinoid system in cancerpotential therapeutic target? Semin Cancer Biol 2008; 18(3): 176-89.
36. Larrinaga G, Sanz B, Perez I, et al. Cannabinoid CB(1) receptor is downregulated in clear cell renal cell carcinoma. J Histochem Cytochem 2010; 58(12): 1129-34.
37. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Diaz-Laviada I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 2009; 101(6): 940-50.
38. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17(3): 529-31.
39. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55(3): 597-602.
40. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006; 95(2): 197-203.
41. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6(1): 35-42.
42. Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP. Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003; 56(1): 1-12.
43. Ruiz L, Miguel A, Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptorindependent mechanism. FEBS Lett 1999; 458(3): 400-4.
44. Sanchez C, de Ceballos ML, Gomez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61(15): 5784-9.
45. Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ. Serumdependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 2000; 60(12): 1807-13.
46. Casanova ML, Blazquez C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111(1): 43-50.
47. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95(2): 175-84.
48. Liu J, Gao B, Mirshahi F, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346 Pt 3: 835-40.
49. Gomez del Pulgar T, Velasco G, Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000; 347(Pt 2): 369-73.
50. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312 (Pt 2): 637-41.
51. Bouaboula M, Poinot-Chazel C, Marchand J, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem FEBS 1996; 237(3): 704-11.
52. Sanchez C, Galve-Roperh I, Rueda D, Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 1998; 54(5): 834-43.
53. Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 2008; 14(23): 7691-700.
54. Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 2006; 312(11): 2121-31.
55. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66(13): 6748-55.
56. Malan TP, Jr., Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003; 3(1): 62-7.
57. Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011; 10(1): 90-103.
58. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008; 104(4): 1091-100.
59. Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 2014; 13(12): 2955-67.
60. Solinas M, Massi P, Cinquina V, Valenti M, Bolognini D, Gariboldi M, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PloS One 2013; 8(10): e76918.
61. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6(3): 313-9.
62. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436(1): 6-10.
63. De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998; 95(14): 8375-80.
64. Takeda S, Ikeda E, Su S, et al. Delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells. Toxicology 2014; 326: 18-24.
65. Murase R, Kawamura R, Singer E, et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol 2014; 171(19): 4464-77.
66. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999; 463(3): 235-40.
67. Emery SM, Alotaibi MR, Tao Q, Selley DE, Lichtman AH, Gewirtz DA. Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells. J Pharmacol Exp Ther 2014; 348(2): 293-302.
68. Nasser MW, Qamri Z, Deol YS, et al. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PloS One 2011; 6(9): e23901.
69. Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem Pharmacol 2014; 92(2): 312-25.
70. Ramer R, Bublitz K, Freimuth N, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 2012; 26(4): 1535-48.
71. Ramer R, Heinemann K, Merkord J, et al. COX-2 and PPARgamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013; 12(1): 69-82.
72. Marshall AD, Lagutina I, Grosveld GC. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 2011; 71(24): 7471-80.
73. McKallip RJ, Lombard C, Fisher M, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100(2): 627-34.
74. Wu Z, Shao P, Zhang S, Ling X, Bai M. Molecular imaging of human tumor cells that naturally overexpress type 2 cannabinoid receptors using a quinolone-based near-infrared fluorescent probe. J Biomed Optics 2014; 19(7): 76016.
75. Yrjola S, Sarparanta M, Airaksinen AJ, et al. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. Eur J Pharm Sci 2015; 67: 85-96.
76. Adinolfi B, Romanini A, Vanni A, et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol 2013; 718(1-3): 154-9.
77. Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20(14): 2633-5.
78. Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141(1): 118-26.
79. Orellana-Serradell O, Poblete CE, Sanchez C, et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Reps 2015; 33(4): 1599-608.
80. Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat 2011; 94(1-2): 34-43.
81. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65(5): 1635-41.
82. Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001; 15(14): 2745-7.
83. Cozzolino R, Cali G, Bifulco M, Laccetti P. A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis. Invest New Drugs 2010; 28(2): 115-23.
84. Shi Y, Zou M, Baitei EY, et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 2008; 15(2): 101-7.
85. Brandi J, Dando I, Palmieri M, Donadelli M, Cecconi D. Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. Electrophoresis 2013; 34(9-10): 1359-68.
86. Larrinaga G, Sanz B, Blanco L, et al. Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma. Clin Biochem 2013; 46(7-8): 638-41.
87. Prather PL, FrancisDevaraj F, Dates CR, et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OHTamoxifen. Biochem Biophys Res Commun 2013; 441(2): 339-43.
88. Jan CR, Lu YC, Jiann BP, et al. Novel effect of CP55,940, a CB1/CB2 cannabinoid receptor agonist, on intracellular free Ca2+ levels in bladder cancer cells. Chinese J Physiol 2002; 45(1): 33-9.
89. Gasperi V, Evangelista D, Oddi S, et al. Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors. Life Sci 2015; 138: 41-51.
90. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003; 100(22): 12718-23.
91. Huang Z, Bao SD. Roles of main pro-and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol 2004; 10(4): 463-70.
92. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxiainducible factor 1. Crit Rev Oncol Hematol 2006; 59(1): 15-26.
93. Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 2004; 27(4): 259-64.
94. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10(8): 757-63.
95. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-90.
96. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64(16): 5617-23.
97. Casanova ML, Larcher F, Casanova B, et al. A critical role for rasmediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002; 62(12): 3402-7.
98. Blazquez C, Salazar M, Carracedo A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008; 68(6): 1945-52.
99. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9(2): 267-85.
100. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25(1): 9-34.
101. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6(3): 227-39.
102. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7(3): 211-7.
103. Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176(8): 5023-32.
104. Krol M, Mucha J, Majchrzak K, et al. Macrophages mediate a switch between canonical and non-canonical Wnt pathways in canine mammary tumors. PloS One 2014; 9(1): e83995.
105. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475(7355): 222-5.
106. Krol M, Pawlowski KM, Majchrzak K, Gajewska M, Majewska A, Motyl T. Global gene expression profiles of canine macrophages and canine mammary cancer cells grown as a co-culture in vitro. BMC Veterinary Res 2012; 8: 16.
107. Fung S SN. Targeting endocannabinoid signaling in tumorassociated macrophages as treatment for glioblastoma multiforme. WIREs Membr Transp Signal 2014; 3: 39-51.
108. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol 2008; 3(2): 117-29.
109. Ghosh S, Preet A, Groopman JE, Ganju RK. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 2006; 43(14): 2169-79.
110. Murdoch C, Finn A. Chemokine receptors and their role in vascular biology. J Vasc Res 2000; 37(1): 1-7.
111. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54(2): 227-9.
112. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. New Engl J med 2006; 354(6): 610-21.
113. Martin BR. Cellular effects of cannabinoids. Pharmacol Rev 1986; 38(1): 45-74.
114. Makriyannis A, Yang DP, Griffin RG, Das Gupta SK. The perturbation of model membranes by (-)-delta 9-tetrahydrocannabinol. Studies using solid-state 2H-and 13C-NMR. Biochim Biophys Acta 1990; 1028(1): 31-42.
115. Cabral GA, Staab A. Effects on the immune system. Handbook Exp Pharmacol 2005(168): 385-423.
116. Khan MI, Czarnecka AM, Duchnowska R, Kukwa W, Szczylik C. Metastasis-initiating cells in renal cancer. Curr Signal Transduct Ther 2014; 8(3): 240-6.
117. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007; 356(2): 125-34.
118. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009; 21(2): 163-71.
119. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 2011; 30(3-4): 599-612.
120. Larrinaga G, Varona A, Perez I, et al. Expression of cannabinoid receptors in human kidney. Histol Histopathol 2010; 25(9): 1133-8.
121. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014; 64(1): 9-29.